Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
QKI
REST API REST API
Homo sapiens
QKI is differentially expressed in 424 experiments: 220 organism parts: bone marrow, kidney, ... (218 more);, 325 disease states: normal, glioblastoma, ... (323 more);, 148 cell types 564 cell lines 56 compound treatments and 96 other conditions.
Synonyms QK3
Orthologs MSL5 (Saccharomyces cerevisiae)   QKI (Gallus gallus)   ENSCING00000002548 (Ciona intestinalis)   QKI (Bos taurus)   QKI (Danio rerio)   Qk (Rattus norvegicus)   Qk (Mus musculus)   how (Drosophila melanogaster)   qki (Xenopus laevis)   QKI_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, RNA splicing, transport, protein binding, cytoplasm, mRNA transport, positive regulation of gene expression, SH3 domain binding, regulation of translation, multicellular organismal development, nucleus, muscle cell differentiation, mRNA processing, axon ensheathment, RNA binding, long-chain fatty acid biosynthetic process, myelination, vasculogenesis
InterPro Term KH_type_1_subgr, KH
UniProt Accession Q96PU8, B4DHR6, F5H8C8, F5GXS8, F5GYM3, F5GYT7, F5H5U6
Search EB-eye ENSG00000112531
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (37 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, ... (53 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
PC3
3
E-GEOD-14464, E-GEOD-5258, E-MEXP-2034
SW480
3
E-GEOD-18005, E-MTAB-37, E-GEOD-2509
MCF-7
1
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
AGS
2
E-MTAB-37, E-GEOD-15460
MCF-10A
2
E-TABM-420, E-GEOD-14990
558 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (67 experiments)

Factor Value U/D Experiments
macrophage
1
3
E-GEOD-22373, E-GEOD-3982, E-GEOD-8286, E-GEOD-5099
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
142 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (89 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-6014, E-MTAB-62, E-GEOD-4290, E-GEOD-4412, E-MTAB-37 ... (5 experiments)
prostate carcinoma
4
E-MTAB-37, E-MEXP-2034, E-GEOD-7307, E-MTAB-62
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MEXP-231, E-MTAB-62
astrocytoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-4290
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
leiomyosarcoma
2
E-MTAB-62, E-MEXP-1922
319 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-4668, E-GEOD-1417, E-GEOD-5741, E-TABM-782, ... (41 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
saline
1
E-GEOD-3026
nocodazole
1
E-GEOD-5258
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
keratinocyte growth factor
1
E-GEOD-7216
50 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
74.51
1
1
E-TABM-325


Age at diagnosis
studied in E-GEOD-4922

Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-4619, E-GEOD-21589, E-GEOD-16363, ... (13 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, ... (12 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, ... (10 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919, E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-TABM-868, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-GEOD-1926, E-MEXP-1648, E-TABM-15, E-GEOD-3606, ... (49 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-GEOD-980, ... (7 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-22229, E-GEOD-19703, E-GEOD-1309, E-GEOD-22152, E-GEOD-22309, ... (12 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896, E-GEOD-17204

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, ... (6 experiments)

Sex
studied in E-GEOD-2508, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-1295 ... (5 experiments)

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Tumor size
studied in E-GEOD-4922

Processing time: 0.311 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM